Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...
Old image misrepresented as 'Israeli settlers' in northern Thailand after Gaza ceasefire
"Israeli media reports there are Jews who have stopped fighting the wars in Gaza, Palestine, and Lebanon. They moved to ...
jacobin19h
Syria Remains a Battleground for Competing Regional Powers
Turkey’s ruling AKP views the fall of Assad in Syria as an opportunity to project power across the region. But the ...
Nexxen Completes Stock Exchange and Trading Structure Changes
Nexxen’s $50 million Ordinary Share repurchase program will continue on Nasdaq following the Company’s delisting from AIM and is currently expected to continue until May 19, 2025, or completion.